This observational pilot study (n=10) will investigate the reactivity of salivary oxytocin during a single dose of lysergic acid diethylamide (LSD) as part of psychedelic-assisted psychotherapy (PAP) for anxiety disorders or depression.
Conducted at Geneva University Hospitals, Switzerland, under the supervision of Tatiana Aboulafia Brakha, the study aims to assess whether salivary oxytocin can serve as a biomarker for PAP.
Participants, aged 18 to 50, will be individuals undergoing ongoing psychotherapy and approved for compassionate use of LSD. The study will involve four saliva samples taken on the day of treatment, alongside self-reported questionnaires measuring anxiety, depression, mystical experience, and connectedness. Primary and secondary outcomes will be assessed over a six-month period. The study is expected to run from August to December 2024.
Trial Details
The main objective of this pilot study is to obtain preliminary data on the reactivity of salivary oxytocin during a single LSD intake as part of PAP treatment for anxiety disorders or depression (treatment authorisations granted in advance by the Federal Officie of Public Health for compassionate use of the substance). There will be no interference with the usual clinical routine in our Service. The protocol is only for taking additional saliva measurements to measure oxytocin levels on the day of treatment. Participants will be asked to give 4 saliva samples the day of their LSD treatment .In addition they will fill-in self-report questionnaires which are part of the clinical routine.Trial Number NCT06557239
Sponsors & Collaborators
University Hospital GenevaThis company doesn't have a full profile yet, it is linked to a clinical trial.